Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Resmed Inc (RMD)

Resmed Inc (RMD)
185.00 x 1 215.50 x 3
Pre-market by (Cboe BZX)
214.08 +3.21 (+1.52%) 04/22/25 [NYSE]
185.00 x 1 215.50 x 3
Pre-market 215.09 +1.01 (+0.47%) 06:56 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
211.10
Day High
215.07
Open 212.47
Previous Close 210.87 210.87
Volume 1,365,800 1,365,800
Avg Vol 1,267,985 1,267,985
Stochastic %K 52.50% 52.50%
Weighted Alpha -5.46 -5.46
5-Day Change -0.45 (-0.21%) -0.45 (-0.21%)
52-Week Range 179.00 - 263.05 179.00 - 263.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,441,288
  • Shares Outstanding, K 146,867
  • Annual Sales, $ 4,685 M
  • Annual Income, $ 1,021 M
  • EBIT $ 1,605 M
  • EBITDA $ 1,821 M
  • 60-Month Beta 0.75
  • Price/Sales 6.61
  • Price/Cash Flow 23.08
  • Price/Book 5.95

Options Overview Details

View History
  • Implied Volatility 50.01% ( -0.15%)
  • Historical Volatility 36.05%
  • IV Percentile 94%
  • IV Rank 67.98%
  • IV High 63.20% on 08/01/24
  • IV Low 22.00% on 05/09/24
  • Put/Call Vol Ratio 0.31
  • Today's Volume 405
  • Volume Avg (30-Day) 613
  • Put/Call OI Ratio 2.30
  • Today's Open Interest 13,396
  • Open Int (30-Day) 21,596

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.36
  • Number of Estimates 7
  • High Estimate 2.41
  • Low Estimate 2.32
  • Prior Year 2.13
  • Growth Rate Est. (year over year) +10.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
199.92 +7.08%
on 04/07/25
Period Open: 219.70
227.00 -5.69%
on 03/25/25
-5.62 (-2.56%)
since 03/21/25
3-Month
199.92 +7.08%
on 04/07/25
Period Open: 247.33
263.05 -18.62%
on 01/30/25
-33.25 (-13.44%)
since 01/22/25
52-Week
179.00 +19.60%
on 04/25/24
Period Open: 180.35
263.05 -18.62%
on 01/30/25
+33.73 (+18.70%)
since 04/22/24

Most Recent Stories

More News
Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow

Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow

ABT : 131.73 (+1.42%)
RMD : 214.08 (+1.52%)
NEOG : 4.75 (+1.28%)
Resmed Names Salli Schwartz as Chief Investor Relations Officer

RMD.AX : 33.250 (+1.43%)
RMD : 214.08 (+1.52%)
Earnings Preview: What to Expect From ResMed’s Report

ResMed is set to release its fiscal third-quarter earnings this month, with analysts forecasting a lower-double-digit growth in profits.

XLV : 135.06 (+1.88%)
$SPX : 5,287.76 (+2.51%)
RMD : 214.08 (+1.52%)
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

RMD : 214.08 (+1.52%)
MASI : 152.07 (+1.90%)
PODD : 244.02 (+2.28%)
IRTC : 99.48 (+0.86%)
DXCM : 66.33 (+0.33%)
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwlâ„¢, Now Available Across the US

RMD.AX : 33.250 (+1.43%)
RMD : 214.08 (+1.52%)
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks

Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks

RMD : 214.08 (+1.52%)
MASI : 152.07 (+1.90%)
IRTC : 99.48 (+0.86%)
PODD : 244.02 (+2.28%)
DXCM : 66.33 (+0.33%)
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

RMD.AX : 33.250 (+1.43%)
RMD : 214.08 (+1.52%)
Is West Pharmaceutical Services Stock Underperforming the S&P 500?

West Pharmaceutical Services has lagged behind the broader S&P 500 Index over the past year, but analysts remain highly optimistic about its future growth potential.

$SPX : 5,287.76 (+2.51%)
RMD : 214.08 (+1.52%)
WST : 215.13 (+4.49%)
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

RMD : 214.08 (+1.52%)
MASI : 152.07 (+1.90%)
PODD : 244.02 (+2.28%)
IRTC : 99.48 (+0.86%)
DXCM : 66.33 (+0.33%)
Is ResMed Stock Outperforming the Dow?

Despite ResMed’s outperformance relative to the Dow Jones over the past year, analysts are cautiously optimistic about the stock’s prospects.

RMD : 214.08 (+1.52%)
$DOWI : 39,186.98 (+2.66%)
ISRG : 478.74 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 219.71
2nd Resistance Point 217.39
1st Resistance Point 215.74
Last Price 214.08
1st Support Level 211.76
2nd Support Level 209.44
3rd Support Level 207.79

See More

52-Week High 263.05
Fibonacci 61.8% 230.94
Fibonacci 50% 221.02
Last Price 214.08
Fibonacci 38.2% 211.11
52-Week Low 179.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro